Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospective cohort study

Journal:

The Lancet Oncology

Published:

2026-02-16

DOI:

10.1016/s1470-2045(25)00717-x

Affiliations:

23

Authors:

22

Go to article

Institutions	Authors	Share
University Medical Center Utrecht (UMC Utrecht), Netherlands	6.500000	0.30
Radiotherapiegroep, Netherlands	2.500000	0.11
Careggi University Hospital (AOUC), UNIFI, Italy	2.000000	0.09
Champalimaud Centre for the Unknown, Portugal	2.000000	0.09
Radboud University Medical Centre (Radboudumc), RU, Netherlands	2.000000	0.09
IRCCS Ospedale Sacro Cuore Don Calabria, Italy	1.500000	0.07
Maria Sklodowska-Curie National Research Institute of Oncology, Poland	1.000000	0.05
Comprehensive Cancer Center Vienna (CCC), Austria	0.611111	0.03
WSB University, Poland	0.500000	0.02
Affidea - Poland, Poland	0.500000	0.02
Medical University of Lublin, Poland	0.500000	0.02
University of Brescia (UNIBS), Italy	0.500000	0.02
University of Latvia (LU), Latvia	0.500000	0.02
Sigulda Hospital, Latvia	0.500000	0.02
I.M. Sechenov First Moscow State Medical University (FMSMU), Russia	0.111111	0.01
The University of Texas Southwestern Medical Center (UT Southwestern Medical Center), United States of America (USA)	0.111111	0.01
Weill Cornell Medicine, United States of America (USA)	0.111111	0.01
Charles University (CU), Czech Republic	0.111111	0.01
The University of Jordan, Jordan	0.111111	0.01
Medical University of Vienna (MUW), Austria	0.111111	0.01
Semmelweis University (SE), Hungary	0.111111	0.01
Tabriz University of Medical Sciences (TUOMS), Iran	0.111111	0.01

Interested in Biomedical Engineering?